Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Immune response modifier post-op
San Francisco - Results from several studies performed with imiquimod 5 percent cream (Aldara, 3M Pharmaceuticals) suggest that the immune response modifier may have a role as a surgical adjuvant for improving local tumor control and/or to enhance scar appearance, says James M. Spencer, M.D., M.S., clinical professor of dermatology, Mt. Sinai School of Medicine, New York.
Recent Videos
Related Content
